• CSPC Pharmaceutical received Chinese regulator clearance to start clinical trials of its recombinant RSV vaccine candidate SYS 6057.
• The trial targets adults aged 60 and older to prevent RSV-related lower respiratory tract disease.
• The candidate uses a pre-fusion F protein antigen with CSPC’s in-house second-generation nano-adjuvant platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260731-12264302), on July 31, 2026, and is solely responsible for the information contained therein.